



ASX release

4 June 2008

## **US \$1.15m new pharmaceutical trials contracts**

### ***Repeat business with major global player***

AtCor Medical (ASX:ACG) today announced that it has signed agreements to supply SphygmoCor<sup>®</sup> systems and clinical trial support services for upcoming pharmaceutical clinical trials. The minimum total value of these contracts is USD\$1.15 million, a significant portion of which will be recognised as revenue in the current financial year. Over 70 percent of these transactions are repeat business following successful use of SphygmoCor<sup>®</sup> in earlier trials by the same client company. The new trials will take place at sites in the US and Europe.

Commenting on the repeat business, Duncan Ross, CEO of AtCor Medical said “We are delighted that our SphygmoCor<sup>®</sup> technology and clinical trial support services will continue to play an important role in this major pharmaceutical company’s ongoing clinical trial activities. Our team looks forward to the continued strengthening of our mutually beneficial relationship with this important customer.”

Mr Ross added, “Our pharmaceutical trials business continues to grow as evidence mounts that traditional brachial cuff pressures do not provide a complete understanding of a drug’s mechanisms of action and efficacy. Recent publications have further enhanced the importance of this point, adding to the growing body of evidence that central blood pressures – those experienced by the heart, brain and kidneys – are a much more sensitive measure of cardiovascular risk than pressures measured in the arm. The bottom line is that important benefits of, and differences between, competing drug compounds are not always detectable from measurements made with the brachial cuff.”

### **About AtCor Medical**

AtCor Medical develops and markets products for the early detection of cardiovascular risk and management of cardiovascular disease. Its technology allows researchers and clinicians to assess central blood pressure non-invasively. The company’s SphygmoCor<sup>®</sup> system visibly identifies the effects of reflected blood pressure in the central aortic pressure wave, effects which cannot be detected with standard blood pressure monitoring. More than 1,400 SphygmoCor<sup>®</sup> systems are currently in use worldwide at major medical institutions research institutions and in various clinical trials with leading pharmaceutical companies, and the company’s technology has been featured in over 200 peer-reviewed studies published in leading medical journals. AtCor has operations in Australia, the United States, and Europe. For further information, please visit our web site at [www.atcormedical.com](http://www.atcormedical.com)

*For further information, please contact:*

Duncan Ross – AtCor Medical CEO  
+1 (630) 228 8874

Peter Manley – AtCor Medical CFO  
+61 (2) 9874 8761

*Media enquiries to:*

Ashley Rambukwella – Financial &  
Corporate Relations  
Ph: +61 (2) 8264 1004/ m. 0407 231 282 or  
[a.rambukwella@fcr.com.au](mailto:a.rambukwella@fcr.com.au)

SphygmoCor<sup>®</sup> is a registered trademark of AtCor Medical Pty Ltd and its related entities.